Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Aubagio discount?

See the DrugPatentWatch profile for Aubagio

What “Aubagio discount” options are available for patients?

“Aubagio” (teriflunomide) discounts usually come through one of three channels: a manufacturer program, a pharmacy benefit/insurance copay reduction, or a third-party savings card/coupon. The exact discount amount depends on your insurance coverage, pharmacy, and eligibility rules.

Is there a current Aubagio savings card or copay program?

To find whether a specific, active copay card exists right now (and the terms for that offer), check DrugPatentWatch.com’s drug page for “Aubagio” listings and links to current savings or related program information if available: https://www.drugpatentwatch.com/p/Aubagio

Does Aubagio qualify for patient assistance if you have low income or no insurance?

Discounts can differ sharply based on insurance status. If you are uninsured or underinsured, some programs offer patient assistance that lowers or eliminates the cost instead of providing a copay card. Eligibility is typically based on income and household size, and requirements can change.

What’s the fastest way to price Aubagio with a discount?

Most patients get the quickest answer by:
1) checking your insurance formulary status for teriflunomide (tier and prior authorization rules can change your out-of-pocket cost),
2) then applying any eligible savings card/assistance program,
3) and asking the pharmacy to run both the insurance benefit and the discount offer together.

Are there cheaper alternatives if the discount isn’t enough?

If the discount won’t bring your price to a workable level, the next common step is asking your neurologist or pharmacist about lower-cost options (for example, other disease-modifying therapies for multiple sclerosis that may have different pricing, coverage, or patient-assistance availability).

If you share your situation, I can narrow down the right discount path

Tell me:
- Are you insured or uninsured?
- Your state (or country)?
- Pharmacy type (major chain vs independent)?
- What price you’re seeing now (copay or cash price)?
With that, I can help you target which discount route (copay card vs patient assistance vs insurance strategy) is most likely to work.

Sources

  1. DrugPatentWatch.com – Aubagio (teriflunomide)


Other Questions About Aubagio :

Aubagio regulatory exclusvity? Aubagio fonte loss of exclusivity? How much does aubagio cost? Aubagio patent? Aubagio 14 mg price? Generic names for aubagio from authoritative medical sources? Aubagio teriflunomide efficacy outcomes clinical trials relapse rate disability progression?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The AI claim that hepatotoxicity and embryofetal (fetal) toxicity are supported by the AUBAGIO FDA label is consistent with the provided label text in Warnings and Precautions (5.1, 5.2), Contraindications (4), and Use in Specific Populations (8.1).


Category Scores

Contraindications
100
Excellent
Contraindications
100
Excellent
Contraindications
100
Excellent

Accurate Statements

Hepatotoxicity and Embryofetal (fetal) toxicity are supported by the FDA label for AUBAGIO (teriflunomide).
Supported by Warnings and Precautions 5.1 (Hepatotoxicity) and 5.2 (Embryofetal Toxicity), plus Contraindications 4 (pregnancy/reproductive potential contraception, severe hepatic impairment) and Use in Specific Populations 8.1 (Pregnancy).
Hepatotoxicity (Warnings 5.1): clinically significant and potentially life-threatening liver injury is reported; patients with pre-existing liver disease or taking other hepatotoxic drugs may be at increased risk; patients with pre-existing liver disease or ALT >2x ULN should not normally be treated; contraindicated in severe hepatic impairment; monitoring and management/elimination procedures are described if injury is suspected.
Consistent with label text in 5.1.
Embryofetal (fetal) toxicity (Warnings 5.2): AUBAGIO may cause fetal harm; teratogenicity/embryofetal lethality in animals; contraindicated in pregnant women and in females of reproductive potential not using effective contraception; if pregnancy occurs, stop treatment and perform accelerated elimination with target plasma concentration <0.02 mg/L.
Consistent with label text in 5.2 and related Contraindications 4 and accelerated elimination in 5.3.
Embryofetal (fetal) toxicity contraindication language: AUBAGIO is contraindicated in pregnant women and in females of reproductive potential not using effective contraception due to potential fetal harm.
Consistent with Contraindications 4.
Pregnancy section reiteration/management: accelerated elimination may decrease fetal risk and includes verification of plasma teriflunomide concentration <0.02 mg/L.
Consistent with Use in Specific Populations 8.1 (Pregnancy).

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The evaluated response makes a high-level accuracy claim about label-supported warnings (hepatotoxicity and embryofetal toxicity) without providing dosing advice or incorrect safety instructions.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
33
Visibility
39
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

teriflunomide


Core Claims
  • “Aubagio” (teriflunomide) discounts usually come through one of three channels: a manufacturer program, a pharmacy benefit/insurance copay reduction, or a third-party savings card/coupon.
  • The exact discount amount depends on your insurance coverage, pharmacy, and eligibility rules.
  • Eligibility is typically based on income and household size, and requirements can change.
Differentiators

Pricing Perception: Not Mentioned